Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV-2 | 3 | 2019 | 92 | 1.05 | Why? |
| Hyaluronan Receptors | 1 | 2018 | 61 | 0.72 | Why? |
| Immunomagnetic Separation | 1 | 2018 | 55 | 0.71 | Why? |
| Virus Cultivation | 1 | 2018 | 579 | 0.55 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 533 | 0.48 | Why? |
| Antibodies | 1 | 2018 | 846 | 0.44 | Why? |
| Multiplex Polymerase Chain Reaction | 4 | 2021 | 1439 | 0.39 | Why? |
| HIV Infections | 7 | 2019 | 11620 | 0.37 | Why? |
| Drug Resistance, Viral | 3 | 2018 | 1083 | 0.33 | Why? |
| beta-Cyclodextrins | 2 | 2020 | 87 | 0.26 | Why? |
| Virus Diseases | 1 | 2021 | 3779 | 0.25 | Why? |
| Furans | 2 | 2020 | 156 | 0.25 | Why? |
| Coinfection | 2 | 2021 | 6820 | 0.23 | Why? |
| Triazines | 2 | 2020 | 246 | 0.23 | Why? |
| Pyrroles | 2 | 2020 | 292 | 0.21 | Why? |
| Papillomavirus Infections | 2 | 2019 | 861 | 0.20 | Why? |
| Guinea-Bissau | 1 | 2019 | 22 | 0.20 | Why? |
| Respiratory Tract Infections | 1 | 2021 | 6817 | 0.20 | Why? |
| APOBEC-3G Deaminase | 1 | 2018 | 33 | 0.19 | Why? |
| HIV-1 | 3 | 2018 | 3365 | 0.18 | Why? |
| Miners | 1 | 2017 | 19 | 0.17 | Why? |
| Mining | 1 | 2017 | 32 | 0.17 | Why? |
| Alphapapillomavirus | 1 | 2018 | 107 | 0.17 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 95 | 0.16 | Why? |
| Clinical Laboratory Techniques | 6 | 2021 | 23402 | 0.16 | Why? |
| Paris | 1 | 2021 | 1287 | 0.16 | Why? |
| Superinfection | 1 | 2021 | 459 | 0.16 | Why? |
| Capsid | 1 | 2017 | 197 | 0.15 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2021 | 13720 | 0.15 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.15 | Why? |
| Adenosine Monophosphate | 3 | 2020 | 5652 | 0.14 | Why? |
| Alanine | 3 | 2020 | 5687 | 0.14 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.13 | Why? |
| Molecular Diagnostic Techniques | 2 | 2020 | 4239 | 0.13 | Why? |
| Gold | 1 | 2017 | 592 | 0.12 | Why? |
| Viral Load | 7 | 2021 | 15850 | 0.12 | Why? |
| Digestive System Diseases | 1 | 2017 | 378 | 0.12 | Why? |
| Lung Transplantation | 2 | 2020 | 1554 | 0.12 | Why? |
| Sexually Transmitted Diseases | 1 | 2019 | 694 | 0.11 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2020 | 1138 | 0.11 | Why? |
| Respiratory System | 2 | 2020 | 3213 | 0.11 | Why? |
| Mutation | 4 | 2018 | 12376 | 0.11 | Why? |
| Homosexuality, Male | 1 | 2019 | 1158 | 0.10 | Why? |
| Anemia | 1 | 2017 | 789 | 0.10 | Why? |
| France | 6 | 2021 | 12074 | 0.10 | Why? |
| Serologic Tests | 2 | 2020 | 4359 | 0.10 | Why? |
| Anti-HIV Agents | 2 | 2018 | 2209 | 0.09 | Why? |
| Sensitivity and Specificity | 7 | 2021 | 22971 | 0.08 | Why? |
| Viruses | 1 | 2021 | 2238 | 0.08 | Why? |
| Virus Shedding | 2 | 2021 | 5834 | 0.08 | Why? |
| Betacoronavirus | 11 | 2020 | 204454 | 0.08 | Why? |
| Nasopharynx | 3 | 2021 | 10224 | 0.08 | Why? |
| Renal Dialysis | 2 | 2020 | 4358 | 0.08 | Why? |
| Adenosine | 2 | 2020 | 509 | 0.08 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.08 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.08 | Why? |
| Prospective Studies | 6 | 2021 | 43301 | 0.08 | Why? |
| High-Throughput Nucleotide Sequencing | 4 | 2018 | 3633 | 0.08 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Prevalence | 4 | 2021 | 25773 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.07 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.07 | Why? |
| Immunocompromised Host | 1 | 2021 | 5150 | 0.07 | Why? |
| Humans | 28 | 2021 | 930598 | 0.06 | Why? |
| Gene Frequency | 2 | 2018 | 1210 | 0.06 | Why? |
| Cohort Studies | 4 | 2020 | 36005 | 0.06 | Why? |
| Limit of Detection | 2 | 2020 | 2698 | 0.06 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.06 | Why? |
| Male | 16 | 2021 | 367725 | 0.06 | Why? |
| Aged | 11 | 2021 | 215776 | 0.06 | Why? |
| Pharmaceutical Solutions | 1 | 2020 | 24 | 0.06 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.05 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.05 | Why? |
| Neuroglia | 1 | 2020 | 130 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.05 | Why? |
| Reagent Kits, Diagnostic | 2 | 2021 | 2149 | 0.05 | Why? |
| Togo | 1 | 2019 | 95 | 0.05 | Why? |
| Female | 14 | 2021 | 380317 | 0.05 | Why? |
| Immunoprecipitation | 1 | 2020 | 300 | 0.05 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.05 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 8843 | 0.05 | Why? |
| Apolipoproteins B | 1 | 2018 | 47 | 0.05 | Why? |
| Blood | 1 | 2020 | 274 | 0.05 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.05 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 256 | 0.05 | Why? |
| Luciferases | 1 | 2020 | 378 | 0.05 | Why? |
| Suriname | 1 | 2017 | 21 | 0.04 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.04 | Why? |
| HIV Integrase | 1 | 2018 | 67 | 0.04 | Why? |
| HIV Reverse Transcriptase | 1 | 2018 | 104 | 0.04 | Why? |
| Human papillomavirus 16 | 1 | 2018 | 95 | 0.04 | Why? |
| French Guiana | 1 | 2017 | 83 | 0.04 | Why? |
| HIV Protease | 1 | 2018 | 86 | 0.04 | Why? |
| Leishmaniasis | 1 | 2017 | 26 | 0.04 | Why? |
| Cervix Uteri | 1 | 2018 | 146 | 0.04 | Why? |
| Urine | 1 | 2020 | 469 | 0.04 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.04 | Why? |
| Neutralization Tests | 2 | 2020 | 6698 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| Adult | 11 | 2021 | 244371 | 0.04 | Why? |
| Genome, Viral | 1 | 2018 | 13157 | 0.04 | Why? |
| Arbovirus Infections | 1 | 2017 | 104 | 0.04 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Anal Canal | 1 | 2018 | 367 | 0.04 | Why? |
| Papillomaviridae | 1 | 2019 | 404 | 0.04 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2020 | 1444 | 0.03 | Why? |
| Withholding Treatment | 1 | 2020 | 798 | 0.03 | Why? |
| Transplant Recipients | 2 | 2020 | 4982 | 0.03 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.03 | Why? |
| Drug Interactions | 1 | 2020 | 1653 | 0.03 | Why? |
| Administration, Oral | 1 | 2020 | 2340 | 0.03 | Why? |
| Pandemics | 13 | 2021 | 389249 | 0.03 | Why? |
| Switzerland | 1 | 2020 | 2738 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| HIV | 1 | 2019 | 1116 | 0.03 | Why? |
| Sequence Alignment | 1 | 2018 | 2109 | 0.03 | Why? |
| Flow Cytometry | 1 | 2020 | 2393 | 0.03 | Why? |
| Viral Proteins | 2 | 2020 | 7370 | 0.03 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.03 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.02 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.02 | Why? |
| Patient Isolation | 1 | 2021 | 3182 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.02 | Why? |
| Malaria | 1 | 2017 | 1097 | 0.02 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Feces | 1 | 2020 | 4235 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2021 | 6740 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2019 | 4002 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Employment | 1 | 2017 | 1754 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2019 | 3129 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| RNA, Messenger | 1 | 2018 | 5131 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Vulnerable Populations | 1 | 2017 | 3099 | 0.02 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.01 | Why? |
| Travel | 1 | 2020 | 7220 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2019 | 53120 | 0.01 | Why? |
| Brazil | 1 | 2017 | 12582 | 0.01 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2019 | 43792 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2017 | 29620 | 0.01 | Why? |